An excited world welcomes Oxford’s malaria vaccine candidate

Malaria causes more than 400,000 deaths a year, mostly among children in Africa.

The world is hailing the results of the trial of a malaria vaccine from the University of Oxford which indicated it was 77 per cent effective against a disease that kills more than a hundred thousand annually in Nigeria. The jab, known as R21, is the first that could surpass the World Health Orga

```

Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```